Original InvestigationEffect of Prasugrel Pre-Treatment Strategy in Patients Undergoing Percutaneous Coronary Intervention for NSTEMI: The ACCOAST-PCI Study
Key Words
Abbreviations and Acronyms
Cited by (0)
The trial was sponsored by Daiichi Sankyo Co., Ltd., and Eli Lilly and Company, and the coordinating center was the ACTION Study Group at the Institute of Cardiology of Pitié-Salpêtrière Hospital. Data were collected, managed, and analyzed by a clinical research organization contracted by the sponsors according to the protocol and a pre-defined statistical analysis plan.
Dr. Montalescot has received consulting fees from Bayer, Boehringer Ingelheim, CFR, Europa, GLG, Iroko Cardio International, Lead-Up, LLC, Luminex, McKinsey, Remedica, Servier, TIMI Group, WebMD, and Wolters; consulting fees and grant support from Bristol-Myers Squibb, AstraZeneca, Biotronik, Eli Lilly, The Medicines Company, Medtronic, Menarini, Sanofi, Pfizer, and Accumetrics; and grant support from Abbott Vascular, Daiichi Sankyo, Nanospheres, and Stentys. Dr. Collet has received research grants from Bristol-Myers Squibb, Sanofi, Eli Lilly, Guerbet Medical, Medtronic, Boston Scientific, Cordis, Stago, Centocor, Fondation de France, INSERM, Fédération Française de Cardiologie and Société Française de Cardiologie; consulting fees from Sanofi, Eli Lilly, and Bristol-Myers Squibb; and lecture fees from Bristol-Myers Squibb, Sanofi, and Eli Lilly.
Dr. Bolognese has received fees for board membership from Daiichi Sankyo and Eli Lilly; consulting fees from Daiichi Sankyo; and lecture fees from Daiichi Sankyo, Eli Lilly, Menarini, Abbott, AstraZeneca, and Iroko Cardio International. Dr. ten Berg has received fees for board membership from AstraZeneca; consulting fees from AstraZeneca, Eli Lilly, and Merck; and lecture fees from AstraZeneca and Eli Lilly. Dr. Dudek has received consulting and lecture fees from Abbott, Adamed, Adyton Medical Polska, Abiomed Europe, AstraZeneca, Biotronik, Balton, Bayer, Braun, BioMatrix, Boston Scientific, Boehringer Ingelheim, Bracco, Bristol-Myers Squibb, Comesa Polska, Cordis, Cook, Covidien Polska, DRG MedTek, Eli Lilly, EuroCor, Hammermed, GE Healthcare, GlaxoSmithKline, Inspire-MD, Iroko Cardio International, Medianet, Medtronic, The Medicines Company, Meril Life Sciences, Merck Sharp & Dohme, Orbus-Neich, Pfizer, Possis, ProCardia Medical, Promed, REVA Medical, Sanofi, Siemens, Solvay, Stentys, St. Jude Medical, Terumo, Tyco, and Volcano. Dr. Hamm has received payment for board membership from AstraZeneca, Medtronic, and Boehringer Ingelheim; consulting and lecture fees from Medtronic, Boehringer Ingelheim, Eli Lilly, The Medicines Company, Abbott Vascular, Bayer, Sanofi, Boston Scientific, Correvio, Roche Diagnostics, Pfizer, Cordis, Daiichi Sankyo, and GlaxoSmithKline; and lecture fees from AstraZeneca and Merck. Dr. Widimsky has received consulting and lecture fees from Eli Lilly and Daiichi Sankyo. Dr. Tanguay has received consulting fees from Eli Lilly, AstraZeneca, Abbott Vascular, Roche, and GlaxoSmithKline; lecture fees from Sanofi, Eli Lilly, AstraZeneca, Abbott Vascular, Pfizer, and Bristol-Myers Squibb; and grant support from Eli Lilly, AstraZeneca, Roche, Hexacath, Ikaria, Abbott Vascular, GlaxoSmithKline, Roche, and Sanofi. Dr. Goldstein has received fees for board membership from Boehringer Ingelheim, The Medicines Company, and Daiichi-Sankyo; consulting fees from Boehringer Ingelheim, Bayer, Sanofi, and AstraZeneca; lecture fees from Boehringer Ingelheim, The Medicines Company, Daiichi-Sankyo, Bayer, Sanofi, and AstraZeneca; payment for the development of educational presentations from Boehringer Ingleheim and AstraZeneca; and travel support from Boehringer Ingelheim, Daiichi-Sankyo, and Sanofi. Dr. Brown, Ms. Miller, and Dr. LeNarz are employees of and hold stock in Eli Lilly. Dr. Vicaut has received fees for board membership from CERC; consulting fees from Eli Lilly, Novartis, Pfizer, Sanofi, LFB, Abbott, Fresenius, Medtronic, and Hexacath; lecture fees from Novartis; and grant support from Sanofi, AstraZeneca, and Boehringer Ingelheim. Dr. Ecollan has reported that he has no relationships relevant to the contents of this paper to disclose.